Congenital Hyperinsulinism International’s Post

Our viewpoint on Depemokimab is now available in Med by Cell Press. In this article, we examine the recent SWIFT trial results and discuss the potential strengths and weaknesses of this new ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma. Claudia Crimi Link to the article: https://lnkd.in/dykgHeRH #asthma #depemokimab #eosinophils

Despite innovations in biologics and small molecules, current therapies for autoimmune diseases like systemic lupus erythematous (SLE) often only provide short-term symptom control. Patients need treatments that deliver more durable remissions. In this article with Springer Nature, we explore: 🔹The overactive immune response, driven by B cells and/or T cells, and how this may contribute to the pathogenesis of autoimmune diseases. 🔹T cell engagers (TCEs) as a promising modality to deliver deep B cell depletion for autoimmune disease where pathogenic B cells play a key role. 🔹Our investigation of a CD19-targeted TCE which may provide a convenient, off-the-shelf option with the potential to improve upon current standards of care. Read the full article: https://bit.ly/48DPw16

Today, we announced the first participants dosed in Phase 1 trials of our novel half-life extended anti-TL1A antibodies.   This milestone represents another important step on our journey to develop our TL1A program as a monotherapy and combination therapy for the treatment of Inflammatory Bowel Disease (IBD) and in indications beyond IBD.   To learn more, read the full release and forward-looking statement disclosures here: https://lnkd.in/eYSKcCiY   #IBD #biotech

Preventing CRS and ICANS Across Sites of Care: Panelists discuss understanding institutional protocols for managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) prophylaxis in bispecific antibody therapy, along with criteria for safely selecting patients for outpatient step-up dosing. #finance #pharmacy #lifesciences

Can redirecting T cells with a T cell engager change the course of SLE and other AID? Learn more here.

This study provides evidence that clinically and readily available blood biomarkers can be used to provide objective evidence for the wearing-off phenomenon during treatment with anti-CD20 monoclonal antibodies and may provide a tool to modify the dosing schedule in some patients to avoid such wearing-off symptoms. https://lnkd.in/eM76ipXK #MS #multiplesclerosis #ocrelizumab

"We develop our therapeutics based on inhalation, providing our drugs directly to the patient's lungs, which is the primary site of inflammation," explains Dr. Rüdiger Jankowsky, CEO of AATec Medical, at #BIOEurope2024. AATec’s innovative alpha-1-antitrypsin-(AAT)-based protein-inhalation approach aims to provide fast-acting, effective treatments for COPD, bronchiectasis, and other lung diseases, addressing urgent patient needs.   📹 Watch the interview below to learn more about AATec’s mission, or visit us on YouTube for more insights from BIO-Europe 2024: https://bit.ly/4fzvTcR

An editorial in the European Heart Journal discusses ANGPTL3 inhibition with evinacumab for homozygous familial hypercholesterolemia (HoFH). Evinacumab is a monoclonal antibody that inhibits ANGPTL3, resulting in a increased activity of lipoprotein lipase (LPL) and endothelia lipase (EL), decreased conversion of VLDL to LDL and increasing hepatic clearance of VLDL remnants. The final result is major decreases in LDL-C, ApoB, and triglycerides and minor decreases in Lp(a) and is expected to result in decreased risk of heart attacks. I recommend reading the editorial because HoFH is a rare disease giving us an overview of tacking lipoprotein-related cardiovascular risk. [This post was prescheduled due to the holiday of Shavuot on 6/12-13.] #ldl #apob #hypercholesterolemia #cholesterol #cardiovasculardisease #prevention https://lnkd.in/eDzxCpn6

Read our latest technical overview on Therapeutic Targeting of Thymic Stromal Lymphopoietin (TSLP) in Asthma and COPD! Learn about TSLP's role in respiratory conditions and its implications for therapy. Find enabling solutions for TSLP drug discovery with our TSLP-responsive luciferase reporter cell line as well as our TSLPR:TSLP Inhibitor Screening Chemiluminescence Assay Kit. #TSLP #cellline #drugdiscovery https://hubs.ly/Q02Cj-KL0

Treatment for high Lipoprotein(a) levels shows promising results. A small RCT, published in JAMA has found that Zerlasiran (by Silence Therapeutics plc) can reduce levels by 30%, with no adverse events recorded. Raised #Lipoprotein(a) is known causal risk factor for atherosclerotic cardiovascular disease, and so has been increasingly promoted as an important biomarker to identify #CVD risk. (link in comment) Whilst identifying this important risk factor can help inform patients of the need to take steps to reduce their overall cardiovascular disease risk, by addressing other causal risk factors, measurement of the #biomarker will be much more powerful when there is treatment to reduce levels. Whilst we await more research, and subsequent regulatory approval of Lipoprotein(a)-lowering medication, continued advances in biomarker technologies will mean that patients will be armed with the #healthdata to make important lifestyle decisions and inform conversations with their doctors. Let's continue to #democratisehealthcare and #empowerpatients with data and education.